Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
EXICURE, INC. (XCUR)
|
Add to portfolio |
|
|
|
| Price: |
$0.22
| | Metrics |
| OS: |
8.65
|
M
| |
32
|
% ROE
|
| Market cap: |
$1.92
|
M
| |
22
|
% ROIC
|
|
Net cash:
|
$4.34
|
M
| |
$0.50
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$4.3
|
M
| |
-0.6
|
x EV/EBITDA
|
|
EBIT
|
$3.2
|
M
| |
-0.8
|
x EV/EBIT
|
| EPS |
$1.56
| |
0.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 28.8 | -0.5 | 16.6 | 1.3 | 0.1 | 9.7 | 1.0 | 2.4 |
| Revenue growth | -6068.1% | -102.9% | 1181.9% | 998.3% | -98.8% | 838.1% | -56.6% | |
| Cost of goods sold | 0.0 | -124.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 28.8 | 123.6 | 16.6 | 1.3 | 0.1 | 9.7 | 1.0 | 2.4 |
| Gross margin | 100.0% | -25600.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 19.8 | 49.0 | 32.1 | 19.3 | 14.1 | 13.1 | 13.7 | 10.1 |
| General and administrative | 10.9 | 13.1 | 10.0 | 8.6 | 7.8 | 7.0 | 3.5 | 5.4 |
| EBIT | -1.8 | -62.5 | -25.4 | -26.6 | -21.8 | -10.4 | -16.2 | -13.1 |
| EBIT margin | -6.4% | 12950.1% | -153.1% | -2053.8% | -18490.7% | -107.1% | -1560.0% | -550.4% |
| Pre-tax income | -2.4 | -64.1 | -24.7 | -26.3 | -22.4 | -11.0 | -16.9 | 0.0 |
| Income taxes | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -2.6 | -64.1 | -24.7 | -26.3 | -22.4 | -11.0 | -16.9 | 0.0 |
| Net margin | -9.0% | 13271.6% | -148.5% | -2029.6% | -18994.1% | -113.3% | -1635.2% | 0.0% |
| |
| Diluted EPS | ($0.56) | ($21.70) | ($0.28) | ($0.46) | ($0.54) | ($1.09) | ($149.37) | $0.00 |
| Shares outstanding (diluted) | 4.6 | 3.0 | 87.2 | 57.7 | 41.2 | 10.1 | 0.1 | 108.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|